F-1/A: INLIF Limited Files for U.S. IPO to Fund Expansion of Robotics Business

INLIF Limited, a Cayman Islands holding company operating through its PRC subsidiary Ewatt, has filed for an initial public offering in the U.S. to raise capital for expanding its production, R&D, and sales network.

Summary

• INLIF Limited, a Cayman Islands holding company with primary operations in China through its subsidiary Ewatt, is seeking to raise capital through an IPO of its ordinary shares in the U.S.
• The company plans to list on the Nasdaq Capital Market under the ticker symbol 'INLF'.
• Ewatt specializes in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms.
• The IPO aims to fund the construction of a 5G digital intelligent equipment production base (33%), establish 24 local marketing and service offices in China (25%), build an industrial robot and automation application technology research and development center (17%), and for working capital (25%).
• The company's revenue for the fiscal year 2023 was $12.61 million, with a net income of $1.35 million.
• The initial public offering price is expected to be between $4 and $6 per Ordinary Share.
• The company has submitted the filing application with the CSRC for this offering, as required by the Trial Measures and was advised by the CSRC that the Company has fulfilled the filing procedures required pursuant to the Trial Measures.
• Following the completion of this offering, our officers, directors and other holders of 5% or more of our Ordinary Shares will collectively control approximately 86.2% of our Ordinary Shares (assuming no exercise of underwriters over-allotment option).

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company shows strong revenue growth and expansion plans, it also faces significant risks related to its operations in China, competition, and regulatory uncertainties. The sentiment is cautiously optimistic.

Positives

• The company has experienced significant revenue growth, with a total revenue of $12.61 million in 2023 compared to $6.65 million in 2022.
• The company has a strong focus on research and development, with plans to invest further in this area.
• The company has a broad customer base, with 117 customers in 2023.
• The company has submitted the filing application with the CSRC for this offering, as required by the Trial Measures and was advised by the CSRC that the Company has fulfilled the filing procedures required pursuant to the Trial Measures.

Negatives

• The company operates in a highly competitive market.
• The company is subject to legal and operational risks associated with doing business in China.
• The company relies on a limited number of suppliers for raw materials.
• The company does not intend to pay dividends in the foreseeable future.

Risks

• Chinese regulatory authorities could disallow the holding company structure.
• The company may be influenced by changes in the political and economic policies of the PRC government.
• The Ordinary Shares may be delisted under the HFCA Act.
• The company may be deemed to be a PRC resident enterprise under the Enterprise Income Tax Law.
• The Operating Entity operates in a highly-competitive market and its failure to compete effectively could adversely affect both its and our business, financial condition, and results of operations.
• The Operating Entitys research and development, acquisition and licensing efforts may fail to generate new products.
• Manufacturing problems may cause product launch delays, inventory shortages, recalls or unanticipated costs.
• The Operating Entity may fail to detect or cure defects of its products.
• If the Operating Entity fails to successfully develop and commercialize new industrial manipulator arms in a timely manner, the operating results may be materially adversely affected.
• Our historical growth rates and performance may not be sustainable or indicative of our future growth and financial results. We cannot guarantee that we will be able to maintain the growth rate we have experienced to date.
• If we cannot retain, attract, and motivate key personnel, we may be unable to effectively implement our business plan.
• Damage to our brand image could have a material adverse effect on our growth strategy and our business, financial condition, results of operations and prospects.
• The Operating Entity may be accused of infringing, misappropriating or otherwise violating the intellectual property rights of third parties.
• The Operating Entity may not successfully acquire and integrate other businesses, license rights to technologies or products, form and manage alliances or divest businesses.
• There has been no public market for our Ordinary Shares prior to this offering, and you may not be able to resell our Ordinary Shares at or above the price you pay for them, or at all.
• The initial public offering price for our Ordinary Shares may not be indicative of prices that will prevail in the trading market and such market prices may be volatile.
• You will experience immediate and substantial dilution in the net tangible book value of Ordinary Shares purchased.
• If we fail to implement and maintain an effective system of internal controls or fail to remediate the material weaknesses in our internal control over financial reporting that have been identified, we may fail to meet our reporting obligations or be unable to accurately report our results of operations or prevent fraud, and investor confidence and the market price of our Ordinary Shares may be materially and adversely affected.
• We will incur substantial increased costs as a result of being a public company.
• Substantial future sales of our Ordinary Shares or the anticipation of future sales of our Ordinary Shares in the public market could cause the price of our Ordinary Shares to decline.
• We do not intend to pay dividends in the foreseeable future.
• The market price of our Ordinary Shares may be volatile or may decline regardless of our operating performance, and you may not be able to resell your shares at or above the initial public offering price.
• The price of our Ordinary Shares could be subject to rapid and substantial volatility. Such volatility, including any stock run-ups, may be unrelated to our actual or expected operating performance and financial condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our Ordinary Shares.
• Our management has broad discretion to determine how to use the funds raised in the offering and may use them in ways that may not enhance our results of operations or the price of our Ordinary Shares.
• If we cease to qualify as a foreign private issuer, we would be required to comply fully with the reporting requirements of the Exchange Act applicable to U.S. domestic issuers, and we would incur significant additional legal, accounting and other expenses that we would not incur as a foreign private issuer.
• Because we are a foreign private issuer and are exempt from certain Nasdaq corporate governance standards applicable to U.S. issuers, you will have less protection than you would have if we were a domestic issuer.
• If we cannot continue to satisfy the listing requirements and other rules of the Nasdaq Capital Market, our securities may be delisted, which could negatively impact the price of our securities and your ability to sell them.

Future Outlook

The company intends to use approximately 33% of the proceeds from this offering for the construction of our 5G digital intelligent equipment production base, approximately 25% of the proceeds from this offering for establishing 24 local marketing and service offices within the PRC, approximately 17% of the proceeds from this offering for the construction of an industrial robot and automation application technology research and development center, and approximately 25% of the proceeds as working capital.

Industry Context

The industrial manipulator arm market in China is fragmented, with increasing demand due to automation in manufacturing. The company competes with both domestic and foreign players, with a focus on quality and customer support.

Comparison to Industry Standards

• The company's market share in China's manipulator arm market was approximately 1.4% in 2022, ranking 10th among all market participants.
• In the injection molding industry, the company's market share was approximately 1.8% in 2022, ranking 8th among all market participants.
• Key competitors include Guangdong Topstar Technology Co., Ltd., Borunte Robot Co., Ltd., GuangDong Switek Technology Co., Ltd., and Abiman Engineering China Co., Ltd.

Related Party Transactions

• The company has engaged in borrowing and sales transactions with related parties, including Wenzao Huang, Yunjun Huang, Xiaolong Chen, and Quanzhou Huasen Hardware and Plastic Products Co., Ltd.

Stakeholder Impact

• Shareholders will experience immediate and substantial dilution in the net tangible book value of Ordinary Shares purchased.
• The company's expansion plans may create new job opportunities.
• Customers may benefit from improved products and services due to increased R&D investment.

Next Steps

• Obtain Nasdaq approval for listing.
• Complete the IPO and receive net proceeds.
• Execute the expansion plans, including construction of the production base and R&D center, and establishment of local marketing offices.

Key Dates

Keywords

IPO, robotics, manipulator arms, Ewatt, INLIF Limited, China, Nasdaq, offering, financials